import type { CompetitorRecord } from './competitor-database';

export const CARDIO_METABOLIC_COMPETITORS: CompetitorRecord[] = [
  // ─────────────────────────────────────────────────────────────────────────────
  // 1. Heart Failure with Reduced Ejection Fraction
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Entresto',
    generic_name: 'sacubitril/valsartan',
    company: 'Novartis',
    indication: 'Heart Failure with Reduced Ejection Fraction',
    indication_specifics: 'Chronic HFrEF (LVEF ≤40%) to reduce cardiovascular death and heart failure hospitalization',
    mechanism: 'Angiotensin receptor-neprilysin inhibitor (ARNI) that simultaneously blocks AT1 receptors and inhibits neprilysin, enhancing natriuretic peptide signaling',
    mechanism_category: 'arni',
    molecular_target: 'AT1 receptor / Neprilysin',
    phase: 'Approved',
    primary_endpoint: 'Composite of cardiovascular death or heart failure hospitalization',
    key_data: 'PARADIGM-HF: 20% RRR in primary composite vs enalapril (p<0.001); NNT=21 over 27 months; also reduced all-cause mortality by 16%',
    line_of_therapy: 'First-line (guideline-directed medical therapy)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Landmark PARADIGM-HF trial demonstrated superiority over ACE inhibitor standard of care',
      'Strong guideline endorsement as foundational HFrEF therapy across ACC/AHA/ESC',
      'Proven mortality benefit with robust real-world evidence confirming trial results',
    ],
    weaknesses: [
      'Hypotension risk limits up-titration in a significant proportion of patients',
      'Requires ACEi/ARB washout period before initiation, complicating transitions',
      'Premium pricing vs generic ACE inhibitors/ARBs despite patent expiry approaching',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jardiance',
    generic_name: 'empagliflozin',
    company: 'Boehringer Ingelheim / Eli Lilly',
    indication: 'Heart Failure with Reduced Ejection Fraction',
    indication_specifics: 'HFrEF (LVEF ≤40%) as add-on to standard of care to reduce cardiovascular death and HF hospitalization',
    mechanism: 'Sodium-glucose co-transporter 2 inhibitor that reduces cardiac preload and afterload, improves myocardial energetics, and provides osmotic diuresis',
    mechanism_category: 'sglt2_inhibitor',
    molecular_target: 'SGLT2',
    phase: 'Approved',
    primary_endpoint: 'Composite of cardiovascular death or hospitalization for heart failure',
    key_data: 'EMPEROR-Reduced: 25% RRR in primary composite vs placebo (p<0.001); significant reduction in HF hospitalizations; benefit consistent regardless of diabetes status',
    line_of_therapy: 'First-line (guideline-directed medical therapy)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Benefits independent of diabetes status, broadening treatable population',
      'Favorable safety profile with low hypotension and renal protective effects',
      'Oral once-daily dosing with no titration required enhances adherence',
    ],
    weaknesses: [
      'Genital mycotic infections and DKA risk require patient education',
      'Competitive SGLT2 inhibitor market with dapagliflozin offering similar data',
      'CV mortality benefit less robust than Entresto in head-to-head comparisons',
    ],
    source: 'Boehringer Ingelheim 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Verquvo',
    generic_name: 'vericiguat',
    company: 'Merck / Bayer',
    indication: 'Heart Failure with Reduced Ejection Fraction',
    indication_specifics: 'Symptomatic chronic HF with recent worsening event (HFrEF after hospitalization or IV diuretic use)',
    mechanism: 'Soluble guanylate cyclase (sGC) stimulator that enhances the NO-sGC-cGMP pathway to improve myocardial and vascular function',
    mechanism_category: 'sgc_stimulator',
    molecular_target: 'Soluble guanylate cyclase',
    phase: 'Approved',
    primary_endpoint: 'Composite of cardiovascular death or first heart failure hospitalization',
    key_data: 'VICTORIA: 10% RRR in primary composite vs placebo (p=0.02); enrolled high-risk patients with recent worsening HF; modest but statistically significant benefit',
    line_of_therapy: 'Add-on therapy for worsening HF',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Addresses unmet need in recently worsening HF population poorly served by other therapies',
      'Novel mechanism complements existing GDMT without overlapping pathways',
      'Oral formulation with once-daily dosing and straightforward titration',
    ],
    weaknesses: [
      'Modest effect size (10% RRR) compared to Entresto and SGLT2 inhibitors',
      'Hypotension is dose-limiting, particularly in already hypotensive HF patients',
      'Limited commercial uptake due to narrow positioning and modest efficacy signal',
    ],
    source: 'Merck 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 2. Heart Failure with Preserved Ejection Fraction
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Jardiance',
    generic_name: 'empagliflozin',
    company: 'Boehringer Ingelheim / Eli Lilly',
    indication: 'Heart Failure with Preserved Ejection Fraction',
    indication_specifics: 'HFpEF (LVEF >40%) to reduce cardiovascular death and heart failure hospitalization',
    mechanism: 'SGLT2 inhibitor providing osmotic diuresis, reduced preload, and improved myocardial energetics independent of glucose-lowering effects',
    mechanism_category: 'sglt2_inhibitor',
    molecular_target: 'SGLT2',
    phase: 'Approved',
    primary_endpoint: 'Composite of cardiovascular death or hospitalization for heart failure',
    key_data: 'EMPEROR-Preserved: 21% RRR in primary composite vs placebo (p=0.002); first therapy to show significant benefit in HFpEF; benefit driven primarily by HF hospitalization reduction',
    line_of_therapy: 'First-line',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Landmark evidence in historically treatment-resistant HFpEF population',
      'Consistent benefit across the LVEF spectrum from mildly reduced to preserved',
      'Well-established safety profile from extensive diabetes and HFrEF experience',
    ],
    weaknesses: [
      'CV mortality benefit not individually significant in EMPEROR-Preserved',
      'Competes directly with dapagliflozin which has similar HFpEF data',
      'Underlying HFpEF heterogeneity means not all phenotypes respond equally',
    ],
    source: 'Boehringer Ingelheim 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Farxiga',
    generic_name: 'dapagliflozin',
    company: 'AstraZeneca',
    indication: 'Heart Failure with Preserved Ejection Fraction',
    indication_specifics: 'HFpEF (LVEF >40%) to reduce worsening heart failure events and cardiovascular death',
    mechanism: 'SGLT2 inhibitor that promotes glucosuria and natriuresis, reducing cardiac volume overload and improving diastolic function',
    mechanism_category: 'sglt2_inhibitor',
    molecular_target: 'SGLT2',
    phase: 'Approved',
    primary_endpoint: 'Composite of worsening heart failure or cardiovascular death',
    key_data: 'DELIVER: 18% RRR in primary composite vs placebo (p<0.001); benefit consistent in patients with LVEF ≥60% and across HFmrEF/HFpEF subgroups',
    line_of_therapy: 'First-line',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'DELIVER trial showed robust benefit across broad HFpEF population including LVEF ≥60%',
      'Complementary renal protection data from DAPA-CKD strengthens cardiorenal value proposition',
      'Oral once-daily with no titration simplifies clinical implementation',
    ],
    weaknesses: [
      'No significant reduction in CV mortality as an individual endpoint',
      'Near-identical mechanism to empagliflozin limits differentiation',
      'Volume depletion and genital infections remain class-level safety concerns',
    ],
    source: 'AstraZeneca 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tirzepatide',
    generic_name: 'tirzepatide',
    company: 'Eli Lilly',
    indication: 'Heart Failure with Preserved Ejection Fraction',
    indication_specifics: 'HFpEF with obesity, targeting the obesity-driven phenotype of HFpEF',
    mechanism: 'Dual GIP/GLP-1 receptor agonist that promotes weight loss, reduces adiposity, and improves metabolic and hemodynamic parameters in obese HFpEF',
    mechanism_category: 'glp1_gip_dual_agonist',
    molecular_target: 'GIP receptor / GLP-1 receptor',
    phase: 'Phase 3',
    primary_endpoint: 'Composite of cardiovascular death or worsening heart failure events',
    key_data: 'SUMMIT Phase 3: tirzepatide reduced composite of CV death or worsening HF by 38% vs placebo (p=0.026) in obese HFpEF; significant improvements in KCCQ and 6MWD Phase 3 as of Jan 2025; regulatory submission anticipated — verify current approval status.',
    line_of_therapy: 'Add-on therapy for obesity-related HFpEF',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Addresses the obesity-HFpEF phenotype, the most prevalent and undertreated HFpEF subgroup',
      'Dramatic weight loss (~13-15%) drives meaningful hemodynamic and symptomatic improvement',
      'Potential to modify disease trajectory rather than just manage symptoms',
    ],
    weaknesses: [
      'Subcutaneous injection with GI side effects (nausea, vomiting) may limit tolerability',
      'Premium biologic pricing in a chronic disease population raises access concerns',
      'Long-term cardiovascular outcomes data still maturing for this specific population',
    ],
    source: 'Eli Lilly 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 3. Metabolic Dysfunction-Associated Steatohepatitis
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Rezdiffra',
    generic_name: 'resmetirom',
    company: 'Madrigal Pharmaceuticals',
    indication: 'Metabolic Dysfunction-Associated Steatohepatitis',
    indication_specifics: 'Non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3) for MASH resolution and fibrosis improvement',
    mechanism: 'Thyroid hormone receptor beta (THR-beta) selective agonist that enhances hepatic lipid metabolism, reduces hepatic fat, and reverses fibrosis',
    mechanism_category: 'thr_agonist',
    molecular_target: 'THR-beta',
    phase: 'Approved',
    primary_endpoint: 'MASH resolution without worsening fibrosis; fibrosis improvement ≥1 stage without worsening MASH',
    key_data: 'MAESTRO-NASH: 26% achieved MASH resolution (80mg) vs 10% placebo (p<0.001); 24% achieved fibrosis improvement (80mg) vs 14% placebo (p<0.01); significant LDL-C and triglyceride reductions',
    line_of_therapy: 'First-line pharmacotherapy',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First and only FDA-approved drug for MASH, establishing first-mover advantage',
      'Dual histological endpoints achieved (MASH resolution and fibrosis improvement)',
      'Additional cardiovascular benefit through significant lipid reductions',
    ],
    weaknesses: [
      'Accelerated approval based on surrogate endpoints; confirmatory outcomes trial ongoing',
      'Diarrhea and nausea affect tolerability in a subset of patients',
      'Requires liver biopsy for diagnosis, creating barriers to identifying eligible patients',
    ],
    source: 'Madrigal 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Semaglutide',
    generic_name: 'semaglutide',
    company: 'Novo Nordisk',
    indication: 'Metabolic Dysfunction-Associated Steatohepatitis',
    indication_specifics: 'MASH with fibrosis (F2-F3) in patients with obesity or type 2 diabetes',
    mechanism: 'GLP-1 receptor agonist that reduces hepatic steatosis via weight loss, improved insulin sensitivity, and direct anti-inflammatory effects on the liver',
    mechanism_category: 'glp1_agonist',
    molecular_target: 'GLP-1 receptor',
    phase: 'Phase 3',
    primary_endpoint: 'MASH resolution without worsening fibrosis',
    key_data: 'Phase 2b: 59% MASH resolution with semaglutide 0.4mg vs 17% placebo (p<0.001); fibrosis improvement trend but not statistically significant; Phase 3 ESSENCE trial ongoing as of Jan 2025 — verify current status.',
    line_of_therapy: 'First-line (anticipated for obese MASH patients)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Massive MASH resolution rates driven by substantial weight loss and metabolic improvement',
      'Established safety profile from extensive GLP-1 RA experience across indications',
      'Addresses the metabolic root cause of MASH in overweight/obese patients',
    ],
    weaknesses: [
      'Fibrosis improvement not yet convincingly demonstrated as standalone endpoint',
      'Subcutaneous injection with significant GI side effects may limit real-world adherence',
      'Supply constraints and high cost of GLP-1 class could limit MASH-specific access',
    ],
    source: 'Novo Nordisk 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Survodutide',
    generic_name: 'survodutide',
    company: 'Boehringer Ingelheim',
    indication: 'Metabolic Dysfunction-Associated Steatohepatitis',
    indication_specifics: 'MASH with liver fibrosis (F1-F3), targeting both MASH resolution and fibrosis improvement',
    mechanism: 'Dual glucagon/GLP-1 receptor agonist that leverages glucagon-mediated hepatic lipid oxidation and GLP-1-mediated appetite suppression and insulin sensitization',
    mechanism_category: 'glucagon_glp1_dual_agonist',
    molecular_target: 'Glucagon receptor / GLP-1 receptor',
    phase: 'Phase 3',
    primary_endpoint: 'MASH resolution without worsening fibrosis; fibrosis improvement ≥1 stage',
    key_data: 'Phase 2: 83% achieved ≥30% relative liver fat reduction; 47% MASH resolution vs 15% placebo (p<0.001); up to 19% body weight loss; fibrosis improvement signals encouraging',
    line_of_therapy: 'First-line (anticipated)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Glucagon component provides direct hepatic fat oxidation beyond weight loss alone',
      'Impressive liver fat reduction and MASH resolution rates in Phase 2',
      'Dual mechanism may offer superior fibrosis improvement over GLP-1-only approaches',
    ],
    weaknesses: [
      'Glucagon agonism raises theoretical concerns about hyperglycemia in diabetic patients',
      'Phase 3 data still pending; Phase 2 results need confirmation at scale',
      'Subcutaneous injection with GI tolerability challenges common to incretin class',
    ],
    source: 'Boehringer Ingelheim 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 4. Heterozygous Familial Hypercholesterolemia
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Repatha',
    generic_name: 'evolocumab',
    company: 'Amgen',
    indication: 'Heterozygous Familial Hypercholesterolemia',
    indication_specifics: 'HeFH as adjunct to diet and maximally tolerated statin therapy for additional LDL-C lowering',
    mechanism: 'Fully human monoclonal antibody that binds PCSK9, preventing its interaction with LDL receptors and increasing LDL-receptor recycling and LDL-C clearance',
    mechanism_category: 'pcsk9_inhibitor',
    molecular_target: 'PCSK9',
    phase: 'Approved',
    primary_endpoint: 'LDL-C % change from baseline',
    key_data: 'RUTHERFORD-2: 59% LDL-C reduction vs placebo in HeFH (p<0.001); FOURIER: 15% RRR in MACE in broad ASCVD population (p<0.001); durable efficacy over 5+ years',
    line_of_therapy: 'Add-on to maximally tolerated statin',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'FOURIER outcomes trial demonstrated significant MACE reduction in high-risk patients',
      'Dramatic ~60% LDL-C lowering enables most HeFH patients to reach treatment targets',
      'Monthly or biweekly self-injection with autoinjector supports home administration',
    ],
    weaknesses: [
      'High cost (~$5,800/year) despite price reductions creates payer access barriers',
      'Injection site reactions and need for cold-chain storage inconvenience patients',
      'Competition from inclisiran (twice-yearly dosing) threatens convenience advantage',
    ],
    source: 'Amgen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Praluent',
    generic_name: 'alirocumab',
    company: 'Sanofi / Regeneron',
    indication: 'Heterozygous Familial Hypercholesterolemia',
    indication_specifics: 'HeFH as adjunct to diet and maximally tolerated statin therapy, including patients with clinical ASCVD',
    mechanism: 'Fully human monoclonal antibody targeting PCSK9 to prevent LDL receptor degradation and enhance hepatic LDL-C clearance',
    mechanism_category: 'pcsk9_inhibitor',
    molecular_target: 'PCSK9',
    phase: 'Approved',
    primary_endpoint: 'LDL-C % change from baseline',
    key_data: 'ODYSSEY FH I/II: 49-58% LDL-C reduction vs placebo in HeFH; ODYSSEY OUTCOMES: 15% RRR in MACE post-ACS (p<0.001); all-cause mortality signal (exploratory)',
    line_of_therapy: 'Add-on to maximally tolerated statin',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'ODYSSEY OUTCOMES showed MACE reduction specifically in post-ACS patients with mortality signal',
      'Dose-adjustment strategy (75mg or 150mg) allows personalization based on LDL-C response',
      'Strong efficacy across HeFH and broad ASCVD populations with consistent ~50-60% LDL-C reduction',
    ],
    weaknesses: [
      'Market share erosion to Repatha and now inclisiran limits growth trajectory',
      'Biweekly injection burden higher than inclisiran twice-yearly dosing',
      'Sanofi return of US rights to Regeneron created commercial transition disruption',
    ],
    source: 'Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Leqvio',
    generic_name: 'inclisiran',
    company: 'Novartis',
    indication: 'Heterozygous Familial Hypercholesterolemia',
    indication_specifics: 'HeFH as adjunct to diet and maximally tolerated statin therapy for LDL-C lowering with twice-yearly dosing',
    mechanism: 'Small interfering RNA (siRNA) that silences PCSK9 mRNA in hepatocytes, providing sustained reduction in PCSK9 protein synthesis and durable LDL-C lowering',
    mechanism_category: 'pcsk9_sirna',
    molecular_target: 'PCSK9 mRNA',
    phase: 'Approved',
    primary_endpoint: 'LDL-C % change from baseline',
    key_data: 'ORION-9 (HeFH): 40% LDL-C reduction vs placebo at day 510 (p<0.001); ORION-10/11: ~50% LDL-C reduction in ASCVD; ORION-4 outcomes trial ongoing',
    line_of_therapy: 'Add-on to maximally tolerated statin',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Twice-yearly in-office dosing eliminates adherence concerns of self-injection biologics',
      'siRNA mechanism provides durable PCSK9 silencing between doses',
      'Physician-administered model ensures consistent dosing and follow-up',
    ],
    weaknesses: [
      'Slightly lower LDL-C reduction (~50%) vs monoclonal antibody PCSK9 inhibitors (~60%)',
      'Cardiovascular outcomes data from ORION-4 not yet available to confirm MACE reduction',
      'Requires office visit for injection, adding healthcare system burden vs home self-injection',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 5. Pulmonary Arterial Hypertension
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Opsumit',
    generic_name: 'macitentan',
    company: 'Johnson & Johnson',
    indication: 'Pulmonary Arterial Hypertension',
    indication_specifics: 'PAH (WHO Group 1) to reduce morbidity and disease progression, as monotherapy or in combination',
    mechanism: 'Dual endothelin receptor antagonist (ERA) with sustained receptor binding that blocks ET-1-mediated vasoconstriction and vascular remodeling in pulmonary arteries',
    mechanism_category: 'endothelin_receptor_antagonist',
    molecular_target: 'Endothelin receptors ETA and ETB',
    phase: 'Approved',
    primary_endpoint: 'Composite of morbidity and mortality (time to first event)',
    key_data: 'SERAPHIN: 45% RRR in morbidity/mortality composite with 10mg vs placebo (p<0.001); benefit maintained in combination with PDE5i; reduced hospitalizations significantly',
    line_of_therapy: 'First-line (combination with PDE5i)',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'SERAPHIN outcomes trial demonstrated morbidity/mortality benefit with long-term data',
      'Improved safety vs older ERA bosentan with lower hepatotoxicity risk',
      'Strong synergy in upfront combination therapy with tadalafil (AMBITION trial backbone)',
    ],
    weaknesses: [
      'Teratogenicity requires strict REMS program limiting prescribing flexibility',
      'Fluid retention and anemia are common dose-dependent side effects',
      'Competition from sotatercept as novel add-on therapy threatens combination share',
    ],
    source: 'Johnson & Johnson 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Uptravi',
    generic_name: 'selexipag',
    company: 'Johnson & Johnson',
    indication: 'Pulmonary Arterial Hypertension',
    indication_specifics: 'PAH (WHO Group 1) to delay disease progression and reduce hospitalization, often as triple combination therapy',
    mechanism: 'Selective prostacyclin IP receptor agonist that provides vasodilation, antiproliferative, and antifibrotic effects in the pulmonary vasculature',
    mechanism_category: 'prostacyclin_receptor_agonist',
    molecular_target: 'Prostacyclin IP receptor',
    phase: 'Approved',
    primary_endpoint: 'Composite of morbidity and mortality (time to first event)',
    key_data: 'GRIPHON: 40% RRR in morbidity/mortality composite vs placebo (p<0.001); benefit on top of ERA and/or PDE5i background therapy; largest PAH outcomes trial conducted',
    line_of_therapy: 'Add-on (triple combination therapy)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only oral prostacyclin pathway agent with event-driven outcomes data (GRIPHON)',
      'Convenient oral dosing vs parenteral prostacyclins (epoprostenol/treprostinil)',
      'Additive benefit when combined with ERA + PDE5i in triple oral combination',
    ],
    weaknesses: [
      'Complex individualized titration with frequent dose adjustments causes treatment delays',
      'Prostacyclin-related side effects (headache, jaw pain, diarrhea, nausea) limit tolerability',
      'Sotatercept offers a new mechanism that may reduce reliance on prostacyclin pathway agents',
    ],
    source: 'Johnson & Johnson 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sotatercept',
    generic_name: 'sotatercept',
    company: 'Merck',
    indication: 'Pulmonary Arterial Hypertension',
    indication_specifics: 'PAH (WHO FC II-III) as add-on to background PAH therapy to improve exercise capacity and reduce disease progression',
    mechanism: 'Activin signaling inhibitor (ActRIIA-Fc fusion protein) that rebalances pro-proliferative and anti-proliferative signaling to reverse pulmonary vascular remodeling',
    mechanism_category: 'activin_signaling_inhibitor',
    molecular_target: 'Activin receptor type IIA (ActRIIA)',
    phase: 'Approved',
    primary_endpoint: '6-minute walk distance (6MWD) change from baseline',
    key_data: 'STELLAR: 40.8m improvement in 6MWD vs placebo (p<0.001); significant improvements in PVR, NT-proBNP, WHO FC, and time to clinical worsening; first-in-class approval 2024',
    line_of_therapy: 'Add-on to background PAH therapy',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class mechanism targeting disease biology (vascular remodeling) rather than just vasodilation',
      'Impressive efficacy across multiple endpoints including 6MWD, PVR, and clinical worsening',
      'Subcutaneous every-3-weeks dosing is convenient relative to parenteral prostacyclins',
    ],
    weaknesses: [
      'Erythrocytosis/polycythemia requires hemoglobin monitoring and potential dose adjustments',
      'Thrombocytopenia and bleeding risk necessitate careful patient selection',
      'Premium biologic pricing on top of existing costly PAH combination therapy',
    ],
    source: 'Merck 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 6. Chronic Thromboembolic Pulmonary Hypertension
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Adempas',
    generic_name: 'riociguat',
    company: 'Bayer',
    indication: 'Chronic Thromboembolic Pulmonary Hypertension',
    indication_specifics: 'Inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy to improve exercise capacity',
    mechanism: 'Soluble guanylate cyclase (sGC) stimulator that enhances the NO-sGC-cGMP signaling pathway to induce pulmonary vasodilation',
    mechanism_category: 'sgc_stimulator',
    molecular_target: 'Soluble guanylate cyclase',
    phase: 'Approved',
    primary_endpoint: '6-minute walk distance (6MWD) change from baseline',
    key_data: 'CHEST-1: 39m improvement in 6MWD vs placebo (p<0.001); significant reduction in PVR; only FDA-approved pharmacotherapy for inoperable CTEPH',
    line_of_therapy: 'First-line pharmacotherapy for inoperable CTEPH',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only approved pharmacotherapy specifically for CTEPH, establishing strong market position',
      'Proven efficacy in both inoperable CTEPH and persistent PH post-endarterectomy',
      'Oral formulation with established titration protocol and long-term safety data',
    ],
    weaknesses: [
      'Contraindicated with PDE5 inhibitors and nitrates, limiting combination strategies',
      'Hypotension and hemoptysis are serious dose-dependent adverse events',
      'Modest exercise capacity improvement; does not address underlying thromboembolic disease',
    ],
    source: 'Bayer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'BPA',
    generic_name: 'balloon pulmonary angioplasty',
    company: 'Procedural',
    indication: 'Chronic Thromboembolic Pulmonary Hypertension',
    indication_specifics: 'CTEPH in patients who are not candidates for pulmonary endarterectomy or with persistent PH post-PEA',
    mechanism: 'Catheter-based interventional procedure that dilates and recanalizes organized thromboembolic obstructions in segmental and subsegmental pulmonary arteries',
    mechanism_category: 'interventional_procedure',
    phase: 'Approved',
    primary_endpoint: '6-minute walk distance (6MWD) and pulmonary vascular resistance (PVR)',
    key_data: 'Registry data: BPA improves 6MWD by 50-70m and reduces PVR by 40-60% over multiple sessions; Japanese and European registries show sustained hemodynamic improvement over 2+ years',
    line_of_therapy: 'Alternative to PEA for inoperable patients',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Directly addresses underlying thromboembolic pathology rather than downstream vasodilation',
      'Can dramatically improve hemodynamics in technically inoperable patients',
      'Complementary to pharmacotherapy; BPA + riociguat combination shows additive benefit',
    ],
    weaknesses: [
      'Requires multiple staged procedures (4-6 sessions) at expert centers with specialized equipment',
      'Risk of reperfusion pulmonary edema and vessel injury during intervention',
      'Limited availability to high-volume specialized centers with experienced operators',
    ],
    source: 'ERS/ESC Guidelines 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sotatercept',
    generic_name: 'sotatercept',
    company: 'Merck',
    indication: 'Chronic Thromboembolic Pulmonary Hypertension',
    indication_specifics: 'Inoperable CTEPH or persistent PH post-PEA/BPA with residual pulmonary vascular remodeling',
    mechanism: 'Activin signaling inhibitor (ActRIIA-Fc fusion protein) targeting pulmonary vascular remodeling by rebalancing TGF-beta superfamily signaling',
    mechanism_category: 'activin_signaling_inhibitor',
    molecular_target: 'Activin receptor type IIA (ActRIIA)',
    phase: 'Phase 3',
    primary_endpoint: '6-minute walk distance (6MWD) and pulmonary vascular resistance (PVR)',
    key_data: 'Phase 3 SOTERIA trial ongoing in CTEPH; PAH data from STELLAR trial supports anti-remodeling mechanism; preclinical data demonstrates efficacy in CTEPH-like models',
    line_of_therapy: 'Add-on therapy',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Anti-remodeling mechanism addresses residual vascular disease not treated by vasodilators or BPA',
      'Strong PAH efficacy data from STELLAR supports biological rationale in CTEPH',
      'Potential to become first add-on therapy to riociguat in CTEPH',
    ],
    weaknesses: [
      'CTEPH pathophysiology differs from PAH; anti-remodeling efficacy must be confirmed',
      'Erythrocytosis risk may be amplified in CTEPH patients with chronic hypoxemia',
      'Phase 3 enrollment challenging due to rare disease with multiple competing interventional approaches',
    ],
    source: 'Merck 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 7. Peripheral Artery Disease
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Cilostazol',
    generic_name: 'cilostazol',
    company: 'Generic',
    indication: 'Peripheral Artery Disease',
    indication_specifics: 'Symptomatic intermittent claudication to improve walking distance and quality of life',
    mechanism: 'Phosphodiesterase 3 (PDE3) inhibitor that increases intracellular cAMP, providing vasodilation, antiplatelet activity, and inhibition of smooth muscle proliferation',
    mechanism_category: 'pde3_inhibitor',
    molecular_target: 'Phosphodiesterase 3',
    phase: 'Approved',
    primary_endpoint: 'Maximal walking distance (treadmill)',
    key_data: 'Meta-analysis: 50% improvement in maximal walking distance vs placebo; superior to pentoxifylline; modest but consistent functional improvement across trials',
    line_of_therapy: 'First-line for symptomatic claudication',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Low-cost generic availability makes it widely accessible for chronic use',
      'Dual vasodilatory and antiplatelet mechanism provides multi-modal PAD benefit',
      'Consistent evidence of walking distance improvement across multiple trials',
    ],
    weaknesses: [
      'Black box warning contraindicating use in any degree of heart failure',
      'Headache, diarrhea, and palpitations lead to significant discontinuation rates',
      'Does not reduce MACE or limb events; purely symptomatic relief',
    ],
    source: 'ACC/AHA PAD Guidelines 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Xarelto',
    generic_name: 'rivaroxaban',
    company: 'Bayer / Johnson & Johnson',
    indication: 'Peripheral Artery Disease',
    indication_specifics: 'PAD with or without prior lower extremity revascularization for reduction of MACE and major adverse limb events',
    mechanism: 'Direct oral factor Xa inhibitor that at vascular dose (2.5mg BID) provides antithrombotic protection in atherosclerotic arterial beds without full anticoagulation intensity',
    mechanism_category: 'doac',
    molecular_target: 'Factor Xa',
    phase: 'Approved',
    primary_endpoint: 'Composite of MACE (CV death, MI, stroke) and major adverse limb events (MALE)',
    key_data: 'COMPASS: Rivaroxaban 2.5mg + aspirin reduced MACE by 24% vs aspirin alone (p<0.001); VOYAGER PAD: 15% RRR in MACE/MALE post-revascularization (p=0.009)',
    line_of_therapy: 'Add-on to aspirin for high-risk PAD',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'COMPASS and VOYAGER PAD provide robust outcomes evidence for vascular-dose rivaroxaban',
      'Reduces both cardiovascular and limb events including acute limb ischemia and amputation',
      'Oral fixed-dose regimen with no monitoring simplifies chronic management',
    ],
    weaknesses: [
      'Increased major bleeding risk (primarily GI) vs aspirin alone requires careful benefit-risk assessment',
      'Vascular dose (2.5mg BID) differs from anticoagulation doses, risking prescribing confusion',
      'Cost premium over aspirin alone in a population often with socioeconomic barriers to care',
    ],
    source: 'Bayer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Vorapaxar',
    generic_name: 'vorapaxar',
    company: 'Merck',
    indication: 'Peripheral Artery Disease',
    indication_specifics: 'PAD with history of MI or symptomatic PAD for secondary prevention of atherothrombotic events',
    mechanism: 'Protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin-mediated platelet activation without affecting thrombin enzymatic activity',
    mechanism_category: 'par1_antagonist',
    molecular_target: 'PAR-1 (thrombin receptor)',
    phase: 'Approved',
    primary_endpoint: 'Composite of cardiovascular death, MI, or stroke',
    key_data: 'TRA 2P-TIMI 50: 13% RRR in MACE vs placebo in overall population (p<0.001); PAD subgroup showed 30% reduction in peripheral revascularization; significant reduction in acute limb ischemia',
    line_of_therapy: 'Add-on to standard antiplatelet therapy',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class PAR-1 antagonist offers unique antiplatelet mechanism complementary to aspirin/P2Y12',
      'Significant reduction in peripheral revascularization and limb events in PAD subgroup',
      'Once-daily oral dosing with long half-life provides consistent platelet inhibition',
    ],
    weaknesses: [
      'Contraindicated in patients with prior stroke/TIA due to increased intracranial hemorrhage risk',
      'Increased bleeding risk without clear mortality benefit limits risk-benefit profile',
      'Very long half-life (~8 days) means effects persist long after discontinuation, complicating surgical planning',
    ],
    source: 'Merck 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 8. Hypertrophic Cardiomyopathy
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Camzyos',
    generic_name: 'mavacamten',
    company: 'Bristol-Myers Squibb',
    indication: 'Hypertrophic Cardiomyopathy',
    indication_specifics: 'Symptomatic obstructive HCM (NYHA class II-III) for reduction of LVOT gradient and improvement in exercise capacity and symptoms',
    mechanism: 'First-in-class cardiac myosin inhibitor that reduces actin-myosin cross-bridge formation, decreasing excessive contractility and LVOT obstruction',
    mechanism_category: 'cardiac_myosin_inhibitor',
    molecular_target: 'Cardiac beta-myosin heavy chain',
    phase: 'Approved',
    primary_endpoint: 'Composite of ≥20 mmHg reduction in post-exercise LVOT gradient to <50 mmHg, and ≥1 NYHA class improvement',
    key_data: 'EXPLORER-HCM: 37% vs 17% achieved primary composite endpoint (p=0.0005); 74% achieved LVOT gradient <30mmHg post-exercise; significant improvement in pVO2 and NYHA class',
    line_of_therapy: 'First-line for symptomatic obstructive HCM',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First disease-specific therapy for HCM targeting the underlying pathophysiology of hypercontractility',
      'Dramatic reduction in LVOT gradients may reduce need for septal reduction procedures',
      'VALOR-HCM showed 82% of patients eligible for SRT no longer met criteria after mavacamten',
    ],
    weaknesses: [
      'Risk of excessive LVEF reduction requiring REMS with regular echocardiographic monitoring',
      'Drug-drug interactions with CYP2C19/CYP3A4 inhibitors require dose adjustments and CYP2C19 genotyping',
      'Narrow therapeutic window requires careful dose titration and ongoing LVEF surveillance',
    ],
    source: 'Bristol-Myers Squibb 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Aficamten',
    generic_name: 'aficamten',
    company: 'Cytokinetics',
    indication: 'Hypertrophic Cardiomyopathy',
    indication_specifics: 'Symptomatic obstructive HCM (NYHA class II-III) for reduction of LVOT gradient and symptom improvement',
    mechanism: 'Next-generation cardiac myosin inhibitor that selectively reduces cardiac myosin ATPase activity and cross-bridge cycling with potentially wider therapeutic window than mavacamten',
    mechanism_category: 'cardiac_myosin_inhibitor',
    molecular_target: 'Cardiac beta-myosin heavy chain',
    phase: 'Phase 3',
    primary_endpoint: 'Change from baseline in peak VO2 at week 24',
    key_data: 'SEQUOIA-HCM: Met primary endpoint with 1.74 mL/kg/min improvement in pVO2 vs placebo (p<0.0001); 95% achieved LVOT gradient <50 mmHg; lower rate of LVEF <50% vs mavacamten',
    line_of_therapy: 'First-line for symptomatic obstructive HCM',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Wider therapeutic window with lower risk of excessive LVEF reduction vs mavacamten',
      'Shorter half-life enables faster washout if LVEF reduction occurs, improving safety management',
      'No CYP2C19 genotyping required and fewer drug-drug interactions simplify prescribing',
    ],
    weaknesses: [
      'Second-to-market vs Camzyos requires differentiation on safety rather than novel mechanism',
      'Phase 3 data still under regulatory review; approval timeline uncertain',
      'Long-term safety and durability data not yet available from extension studies',
    ],
    source: 'Cytokinetics 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'CK-3773274',
    generic_name: 'CK-3773274',
    company: 'Cytokinetics',
    indication: 'Hypertrophic Cardiomyopathy',
    indication_specifics: 'Non-obstructive HCM for improvement of diastolic function and exercise capacity',
    mechanism: 'Cardiac myosin inhibitor designed for non-obstructive HCM phenotype, reducing myocardial hypercontractility and improving diastolic relaxation and compliance',
    mechanism_category: 'cardiac_myosin_inhibitor',
    molecular_target: 'Cardiac beta-myosin heavy chain',
    phase: 'Phase 2',
    primary_endpoint: 'Change in NT-proBNP and echocardiographic measures of diastolic function',
    key_data: 'Phase 2 REDWOOD-HCM cohort 4 evaluating non-obstructive HCM; early signals suggest improvement in NT-proBNP and diastolic parameters; enrollment ongoing',
    line_of_therapy: 'First-line for non-obstructive HCM (investigational)',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Addresses major unmet need in non-obstructive HCM where no disease-specific therapies exist',
      'Leverages cardiac myosin inhibition platform validated by mavacamten and aficamten',
      'Non-obstructive HCM represents ~30% of all HCM patients, a significant untapped population',
    ],
    weaknesses: [
      'Early-stage (Phase 2) with uncertain clinical endpoints for non-obstructive HCM',
      'Non-obstructive HCM is heterogeneous, making patient selection and trial design challenging',
      'Regulatory pathway unclear as no precedent for non-obstructive HCM drug approval exists',
    ],
    source: 'Cytokinetics 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 9. Atrial Fibrillation
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Eliquis',
    generic_name: 'apixaban',
    company: 'Bristol-Myers Squibb / Pfizer',
    indication: 'Atrial Fibrillation',
    indication_specifics: 'Non-valvular atrial fibrillation for reduction of stroke and systemic embolism risk',
    mechanism: 'Direct oral factor Xa inhibitor that selectively and reversibly blocks free and clot-bound factor Xa, reducing thrombin generation without direct effect on platelet aggregation',
    mechanism_category: 'doac',
    molecular_target: 'Factor Xa',
    phase: 'Approved',
    primary_endpoint: 'Stroke or systemic embolism',
    key_data: 'ARISTOTLE: 21% RRR in stroke/systemic embolism vs warfarin (p=0.01); 31% reduction in major bleeding (p<0.001); 11% reduction in all-cause mortality (p=0.047)',
    line_of_therapy: 'First-line anticoagulation',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Superior to warfarin in efficacy (stroke prevention) AND safety (less bleeding) in ARISTOTLE',
      'All-cause mortality reduction uniquely demonstrated among DOACs in AF trials',
      'Market-leading DOAC with largest commercial footprint and physician familiarity',
    ],
    weaknesses: [
      'Twice-daily dosing less convenient than once-daily rivaroxaban or edoxaban',
      'Approaching patent expiry with generic competition expected to erode pricing power',
      'No specific reversal agent as widely available as idarucizumab for dabigatran',
    ],
    source: 'Bristol-Myers Squibb 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Xarelto',
    generic_name: 'rivaroxaban',
    company: 'Bayer / Johnson & Johnson',
    indication: 'Atrial Fibrillation',
    indication_specifics: 'Non-valvular AF for prevention of stroke and systemic embolism',
    mechanism: 'Direct oral factor Xa inhibitor providing predictable anticoagulation without routine monitoring via selective factor Xa blockade',
    mechanism_category: 'doac',
    molecular_target: 'Factor Xa',
    phase: 'Approved',
    primary_endpoint: 'Stroke or systemic embolism',
    key_data: 'ROCKET AF: Non-inferior to warfarin for stroke prevention (HR 0.88, p<0.001 for non-inferiority); similar major bleeding rates; significant reduction in intracranial and fatal bleeding',
    line_of_therapy: 'First-line anticoagulation',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Once-daily dosing offers convenience advantage over twice-daily apixaban',
      'Broadest DOAC indication portfolio spanning AF, VTE, PAD, and CAD',
      'Extensive real-world evidence supporting efficacy and safety across diverse populations',
    ],
    weaknesses: [
      'Non-inferior but not superior to warfarin in ROCKET AF, unlike apixaban in ARISTOTLE',
      'Higher GI bleeding rates compared to warfarin and apixaban',
      'Must be taken with evening meal for adequate absorption, limiting dosing flexibility',
    ],
    source: 'Bayer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Abelacimab',
    generic_name: 'abelacimab',
    company: 'Anthos Therapeutics',
    indication: 'Atrial Fibrillation',
    indication_specifics: 'AF with high bleeding risk for stroke prevention with potentially ultra-low bleeding profile',
    mechanism: 'Anti-factor XI monoclonal antibody that inhibits both activation and activity of factor XI, decoupling thrombosis prevention from hemostatic bleeding risk',
    mechanism_category: 'factor_xia_inhibitor',
    molecular_target: 'Factor XI',
    phase: 'Phase 3',
    primary_endpoint: 'Stroke or systemic embolism (non-inferiority to rivaroxaban)',
    key_data: 'AZALEA-TIMI 71 Phase 2: 67% reduction in major/CRNM bleeding vs rivaroxaban with maintained antithrombotic efficacy; trial stopped early for overwhelming bleeding reduction signal',
    line_of_therapy: 'First-line anticoagulation (high-bleeding-risk patients)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Factor XI inhibition may fundamentally decouple anticoagulation from bleeding risk',
      'Monthly subcutaneous injection eliminates daily pill adherence concerns',
      'AZALEA data showed dramatic bleeding reduction while maintaining stroke prevention signal',
    ],
    weaknesses: [
      'Phase 3 outcomes trial required to confirm stroke prevention non-inferiority at scale',
      'Monthly injection vs daily oral pills may not suit all patients despite adherence benefits',
      'Biologic pricing will create access barriers vs generic DOACs approaching patent expiry',
    ],
    source: 'Anthos Therapeutics 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 10. Deep Vein Thrombosis
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Eliquis',
    generic_name: 'apixaban',
    company: 'Bristol-Myers Squibb / Pfizer',
    indication: 'Deep Vein Thrombosis',
    indication_specifics: 'Treatment of DVT and reduction of risk of recurrent DVT and PE following initial therapy',
    mechanism: 'Direct oral factor Xa inhibitor providing immediate anticoagulation for DVT treatment without need for initial parenteral heparin bridging',
    mechanism_category: 'doac',
    molecular_target: 'Factor Xa',
    phase: 'Approved',
    primary_endpoint: 'Recurrent VTE or VTE-related death',
    key_data: 'AMPLIFY: Non-inferior to standard therapy for recurrent VTE (RR 0.84); 69% reduction in major bleeding vs warfarin (p<0.001); AMPLIFY-EXT showed benefit in extended prophylaxis',
    line_of_therapy: 'First-line treatment',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'No parenteral lead-in required, enabling fully oral single-drug DVT treatment from day one',
      'Dramatically lower major bleeding vs conventional warfarin-based therapy',
      'Proven efficacy in both acute treatment and extended secondary prevention phases',
    ],
    weaknesses: [
      'Twice-daily dosing in acute phase (7 days) then maintenance adds dosing complexity',
      'Not recommended in severe renal impairment or with strong dual CYP3A4/P-gp inhibitors',
      'Lacks validated point-of-care monitoring for perioperative or overdose management',
    ],
    source: 'Bristol-Myers Squibb 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Xarelto',
    generic_name: 'rivaroxaban',
    company: 'Bayer / Johnson & Johnson',
    indication: 'Deep Vein Thrombosis',
    indication_specifics: 'Treatment of DVT and prevention of recurrent DVT and PE',
    mechanism: 'Direct oral factor Xa inhibitor enabling single-drug approach to DVT treatment with dose-adjusted initial intensive and maintenance phases',
    mechanism_category: 'doac',
    molecular_target: 'Factor Xa',
    phase: 'Approved',
    primary_endpoint: 'Recurrent VTE',
    key_data: 'EINSTEIN-DVT: Non-inferior to enoxaparin/VKA for recurrent VTE (HR 0.68); similar major bleeding; EINSTEIN-CHOICE showed superiority of 20mg and 10mg vs aspirin for extended treatment',
    line_of_therapy: 'First-line treatment',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Once-daily dosing (after initial 3-week intensive phase) simplifies long-term maintenance',
      'EINSTEIN-CHOICE provides flexible extended therapy dosing options (10mg or 20mg)',
      'No parenteral lead-in required; single-drug oral pathway from diagnosis',
    ],
    weaknesses: [
      'Higher GI bleeding rates compared to apixaban in indirect comparisons',
      'Requires food for adequate absorption, which may be forgotten by patients',
      'Intensive 15mg BID dosing for first 21 days adds initial complexity',
    ],
    source: 'Bayer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Abelacimab',
    generic_name: 'abelacimab',
    company: 'Anthos Therapeutics',
    indication: 'Deep Vein Thrombosis',
    indication_specifics: 'Extended VTE secondary prevention in patients at high risk of recurrence and bleeding',
    mechanism: 'Anti-factor XI monoclonal antibody that selectively inhibits factor XI to prevent pathological thrombosis while preserving normal hemostatic function',
    mechanism_category: 'factor_xia_inhibitor',
    molecular_target: 'Factor XI',
    phase: 'Phase 2',
    primary_endpoint: 'Recurrent VTE and major/clinically relevant non-major bleeding',
    key_data: 'ANT-005 Phase 2: Dose-dependent reduction in VTE recurrence with very low bleeding rates; 150mg monthly dose showed optimal efficacy-safety balance; further dose optimization ongoing',
    line_of_therapy: 'Extended secondary prevention (investigational)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Factor XI inhibition offers potential for indefinite anticoagulation without bleeding risk accumulation',
      'Monthly subcutaneous injection ideal for extended prevention where adherence declines over time',
      'Addresses critical unmet need for patients who cannot tolerate long-term factor Xa inhibitors',
    ],
    weaknesses: [
      'Phase 2 stage with no pivotal VTE outcomes data yet available',
      'Biologic cost and injection route may limit adoption vs convenient oral DOACs',
      'Optimal dose and patient selection criteria still being defined in ongoing trials',
    ],
    source: 'Anthos Therapeutics 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 11. Dilated Cardiomyopathy
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Entresto',
    generic_name: 'sacubitril/valsartan',
    company: 'Novartis',
    indication: 'Dilated Cardiomyopathy',
    indication_specifics: 'DCM with reduced LVEF as part of guideline-directed HFrEF medical therapy',
    mechanism: 'Angiotensin receptor-neprilysin inhibitor enhancing natriuretic peptides while blocking RAAS to reduce cardiac remodeling and wall stress in dilated ventricles',
    mechanism_category: 'arni',
    molecular_target: 'AT1 receptor / Neprilysin',
    phase: 'Approved',
    primary_endpoint: 'NT-proBNP reduction and LVEF improvement',
    key_data: 'PARADIGM-HF subanalysis: DCM patients showed consistent benefit in CV death/HF hospitalization; PROVE-HF demonstrated significant LVEF improvement (+5.2%) and LV reverse remodeling at 12 months',
    line_of_therapy: 'First-line (guideline-directed medical therapy)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Promotes left ventricular reverse remodeling, directly addressing DCM pathophysiology',
      'Proven mortality benefit in HFrEF population which encompasses most DCM patients',
      'Strong guideline endorsement as foundational GDMT for all HFrEF including DCM etiology',
    ],
    weaknesses: [
      'Not specifically studied in a DCM-only pivotal trial; evidence extrapolated from HFrEF data',
      'Hypotension limits use in DCM patients who often have low baseline blood pressures',
      'Does not address underlying genetic or inflammatory causes of DCM',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jardiance',
    generic_name: 'empagliflozin',
    company: 'Boehringer Ingelheim / Eli Lilly',
    indication: 'Dilated Cardiomyopathy',
    indication_specifics: 'DCM with HFrEF as add-on GDMT for reducing heart failure events and promoting reverse remodeling',
    mechanism: 'SGLT2 inhibitor improving myocardial energetics, reducing interstitial fibrosis, and providing volume optimization in dilated failing ventricles',
    mechanism_category: 'sglt2_inhibitor',
    molecular_target: 'SGLT2',
    phase: 'Approved',
    primary_endpoint: 'Composite of cardiovascular death or hospitalization for heart failure',
    key_data: 'EMPEROR-Reduced: DCM subgroup showed consistent benefit (HR 0.74); EMPA-TROPISM: significant LVEF improvement (+6.0% vs +0.1% placebo, p<0.001) and LV volume reduction in non-diabetic HFrEF',
    line_of_therapy: 'First-line (guideline-directed medical therapy)',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'EMPA-TROPISM demonstrated significant reverse remodeling specifically in non-ischemic cardiomyopathy',
      'Favorable safety profile with additive benefit on top of all other GDMT components',
      'Oral once-daily with no titration reduces burden in patients already on complex regimens',
    ],
    weaknesses: [
      'No DCM-specific pivotal trial; evidence from HFrEF subgroups and small mechanistic studies',
      'Mechanism of cardiac benefit not fully elucidated beyond hemodynamic and metabolic effects',
      'Volume depletion risk in DCM patients who may be sensitive to preload changes',
    ],
    source: 'Boehringer Ingelheim 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Danicamtiv',
    generic_name: 'danicamtiv',
    company: 'Myokardia / Bristol-Myers Squibb',
    indication: 'Dilated Cardiomyopathy',
    indication_specifics: 'DCM with reduced systolic function for improvement in cardiac contractility and ventricular performance',
    mechanism: 'Cardiac myosin activator that stabilizes the pre-powerstroke state of cardiac myosin, increasing the number of cross-bridges formed per cardiac cycle to enhance systolic function',
    mechanism_category: 'cardiac_myosin_activator',
    molecular_target: 'Cardiac beta-myosin heavy chain',
    phase: 'Phase 2',
    primary_endpoint: 'Change in stroke volume (SV) measured by echocardiography',
    key_data: 'Phase 2 PROPEL-HF: Dose-dependent increase in SV and systolic ejection time; improved cardiac output without increasing heart rate or myocardial oxygen demand; well-tolerated across dose levels',
    line_of_therapy: 'Add-on therapy (investigational)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Direct myocardial mechanism addresses the fundamental contractile deficit in DCM',
      'Improves cardiac output without increasing heart rate or myocardial oxygen consumption',
      'Mechanism validated by omecamtiv mecarbil precedent but with improved pharmacology',
    ],
    weaknesses: [
      'Phase 2 stage with no clinical outcomes data yet available',
      'Cardiac myosin activation carries theoretical risk of ischemia in demand-supply mismatch',
      'Omecamtiv mecarbil (same class) showed modest outcomes benefit in GALACTIC-HF, raising efficacy questions',
    ],
    source: 'Bristol-Myers Squibb 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 12. Type 2 Diabetes
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Ozempic',
    generic_name: 'semaglutide',
    company: 'Novo Nordisk',
    indication: 'Type 2 Diabetes',
    indication_specifics: 'T2D as adjunct to diet and exercise for glycemic control, with cardiovascular risk reduction',
    mechanism: 'GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety via central appetite regulation',
    mechanism_category: 'glp1_agonist',
    molecular_target: 'GLP-1 receptor',
    phase: 'Approved',
    primary_endpoint: 'HbA1c reduction',
    key_data: 'SUSTAIN program: HbA1c reduction of 1.5-1.8% across doses; SUSTAIN-6: 26% RRR in MACE (p=0.02); SELECT: 20% MACE reduction in overweight/obese patients without diabetes',
    line_of_therapy: 'Second-line after metformin or first-line if GLP-1 RA preferred',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Best-in-class HbA1c reduction with significant weight loss (4-6 kg) as added benefit',
      'Proven MACE reduction in SUSTAIN-6 and SELECT broadens value beyond glycemic control',
      'Once-weekly injection with high patient satisfaction and strong real-world adherence',
    ],
    weaknesses: [
      'GI side effects (nausea, vomiting, diarrhea) affect 15-20% of patients, especially during titration',
      'Supply constraints due to overwhelming demand limit access and new patient starts',
      'Premium pricing vs oral generics creates significant payer access barriers globally',
    ],
    source: 'Novo Nordisk 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Mounjaro',
    generic_name: 'tirzepatide',
    company: 'Eli Lilly',
    indication: 'Type 2 Diabetes',
    indication_specifics: 'T2D as adjunct to diet and exercise for improved glycemic control with superior weight reduction',
    mechanism: 'Dual GIP and GLP-1 receptor agonist providing synergistic incretin effects with enhanced insulin secretion, appetite suppression, and improved insulin sensitivity beyond GLP-1 alone',
    mechanism_category: 'glp1_gip_dual_agonist',
    molecular_target: 'GIP receptor / GLP-1 receptor',
    phase: 'Approved',
    primary_endpoint: 'HbA1c reduction',
    key_data: 'SURPASS program: HbA1c reduction up to 2.4% (15mg); up to 12.4 kg weight loss; SURPASS-2: superior to semaglutide 1mg in HbA1c and weight reduction (p<0.001 for both)',
    line_of_therapy: 'Second-line after metformin or first-line if GLP-1 RA preferred',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Superior glycemic control and weight loss vs semaglutide in head-to-head SURPASS-2 trial',
      'Dual incretin mechanism achieves near-normalization of HbA1c in majority of patients',
      'Once-weekly injection with potential for best-in-class metabolic outcomes',
    ],
    weaknesses: [
      'Cardiovascular outcomes trial (SURPASS-CVOT) results still pending for formal MACE indication',
      'GI tolerability profile similar to GLP-1 RAs with nausea, diarrhea, and vomiting',
      'High cost and supply limitations in a market requiring chronic treatment of millions of patients',
    ],
    source: 'Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jardiance',
    generic_name: 'empagliflozin',
    company: 'Boehringer Ingelheim / Eli Lilly',
    indication: 'Type 2 Diabetes',
    indication_specifics: 'T2D for glycemic control with proven cardiovascular and renal protective benefits',
    mechanism: 'SGLT2 inhibitor that reduces renal glucose reabsorption, causing glucosuria and caloric loss, while providing hemodynamic and metabolic benefits independent of insulin',
    mechanism_category: 'sglt2_inhibitor',
    molecular_target: 'SGLT2',
    phase: 'Approved',
    primary_endpoint: 'HbA1c reduction',
    key_data: 'EMPA-REG OUTCOME: 38% RRR in CV death (p<0.001); 35% reduction in HF hospitalization; 39% reduction in nephropathy progression; HbA1c reduction ~0.7-0.8%',
    line_of_therapy: 'Second-line (preferred in patients with CVD, HF, or CKD)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Landmark EMPA-REG OUTCOME demonstrated dramatic CV death reduction unmatched by other diabetes drugs',
      'Triple organ protection (heart, kidneys, metabolic) positions it uniquely in T2D with comorbidities',
      'Oral once-daily insulin-independent mechanism complements all other diabetes drug classes',
    ],
    weaknesses: [
      'Modest HbA1c reduction (~0.7%) inferior to GLP-1 RAs and tirzepatide',
      'Genital mycotic infections, DKA risk, and Fournier gangrene (rare) require patient education',
      'Efficacy decreases with declining renal function, limiting use in advanced CKD',
    ],
    source: 'Boehringer Ingelheim 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 13. Obesity
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Wegovy',
    generic_name: 'semaglutide',
    company: 'Novo Nordisk',
    indication: 'Obesity',
    indication_specifics: 'Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity',
    mechanism: 'GLP-1 receptor agonist at obesity dose (2.4mg weekly) that centrally reduces appetite, increases satiety, and slows gastric emptying for sustained caloric reduction',
    mechanism_category: 'glp1_agonist',
    molecular_target: 'GLP-1 receptor',
    phase: 'Approved',
    primary_endpoint: 'Body weight % change from baseline',
    key_data: 'STEP 1: 14.9% weight loss vs 2.4% placebo at 68 weeks (p<0.001); SELECT: 20% RRR in MACE in overweight/obese non-diabetic patients (p<0.001); first anti-obesity drug with CV outcomes benefit',
    line_of_therapy: 'First-line pharmacotherapy',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First anti-obesity medication with proven cardiovascular outcomes benefit (SELECT trial)',
      'Consistent ~15% weight loss across STEP program with high responder rates',
      'Weekly injection with established titration protocol and broad market acceptance',
    ],
    weaknesses: [
      'Weight regain upon discontinuation (STEP-1 extension showed 2/3 regain by 1 year off drug)',
      'Supply constraints and high cost (~$1,350/month) severely limit population-level access',
      'GI side effects (nausea, vomiting, diarrhea) cause 5-7% discontinuation rate',
    ],
    source: 'Novo Nordisk 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zepbound',
    generic_name: 'tirzepatide',
    company: 'Eli Lilly',
    indication: 'Obesity',
    indication_specifics: 'Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity',
    mechanism: 'Dual GIP/GLP-1 receptor agonist providing superior weight loss through synergistic appetite suppression, enhanced energy expenditure, and improved metabolic efficiency',
    mechanism_category: 'glp1_gip_dual_agonist',
    molecular_target: 'GIP receptor / GLP-1 receptor',
    phase: 'Approved',
    primary_endpoint: 'Body weight % change from baseline',
    key_data: 'SURMOUNT-1: 22.5% weight loss with 15mg vs 2.4% placebo at 72 weeks (p<0.001); 63% of patients lost ≥20% body weight; SURMOUNT-2 (T2D): 15.7% weight loss',
    line_of_therapy: 'First-line pharmacotherapy',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Best-in-class weight loss (~22.5%) approaching bariatric surgery efficacy levels',
      'Dual mechanism provides differentiation and potentially broader metabolic benefits',
      'High super-responder rate with majority achieving clinically meaningful ≥10% weight loss',
    ],
    weaknesses: [
      'GI tolerability similar to GLP-1 class with nausea and vomiting during titration',
      'No cardiovascular outcomes data yet (SURMOUNT-MMO ongoing) unlike Wegovy SELECT data',
      'Premium pricing and chronic treatment paradigm raise long-term healthcare cost concerns',
    ],
    source: 'Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Orforglipron',
    generic_name: 'orforglipron',
    company: 'Eli Lilly',
    indication: 'Obesity',
    indication_specifics: 'Chronic weight management as an oral alternative to injectable GLP-1 receptor agonists',
    mechanism: 'Oral non-peptide GLP-1 receptor agonist that activates the GLP-1 receptor with similar pharmacology to peptide-based GLP-1 RAs but via a small molecule amenable to oral delivery',
    mechanism_category: 'glp1_agonist',
    molecular_target: 'GLP-1 receptor',
    phase: 'Phase 3',
    primary_endpoint: 'Body weight % change from baseline',
    key_data: 'Phase 2: Up to 14.7% weight loss at 36 weeks (highest dose) vs 2.3% placebo; dose-dependent efficacy; GI tolerability profile similar to injectable GLP-1 RAs; Phase 3 ATTAIN program initiated',
    line_of_therapy: 'First-line pharmacotherapy (anticipated)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Oral daily pill formulation eliminates injection barrier, potentially expanding addressable market dramatically',
      'Non-peptide structure may enable simplified manufacturing and reduce supply constraints',
      'Phase 2 weight loss approaching injectable GLP-1 RA efficacy with room for dose optimization',
    ],
    weaknesses: [
      'GI tolerability not meaningfully better than injectable GLP-1 RAs in Phase 2',
      'Once-daily fasting requirement (30 min before food) may reduce real-world adherence',
      'Phase 3 data pending; must confirm Phase 2 efficacy translates to pivotal trial success',
    ],
    source: 'Eli Lilly 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 14. Gout
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Krystexxa',
    generic_name: 'pegloticase',
    company: 'Horizon Therapeutics / Amgen',
    indication: 'Gout',
    indication_specifics: 'Chronic refractory gout in patients who have failed conventional urate-lowering therapy, for rapid uric acid lowering and tophus resolution',
    mechanism: 'PEGylated recombinant uricase enzyme that directly metabolizes uric acid to allantoin, bypassing deficient endogenous uricase to achieve rapid and profound uric acid reduction',
    mechanism_category: 'urate_lowering',
    molecular_target: 'Uric acid (enzymatic degradation)',
    phase: 'Approved',
    primary_endpoint: 'Serum uric acid <6 mg/dL maintained over 6 months',
    key_data: 'MIRROR RCT: Immunomodulation with methotrexate increased responder rate to 71% vs 39% without (p<0.01); significant tophus resolution; infusion reactions reduced with co-therapy',
    line_of_therapy: 'Third-line for refractory gout',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Only therapy capable of rapidly dissolving tophi in severe refractory gout',
      'Immunomodulation co-therapy (MTX) dramatically improves response rates and reduces anti-drug antibodies',
      'Addresses critical unmet need in patients who fail allopurinol and febuxostat',
    ],
    weaknesses: [
      'IV infusion every 2 weeks requiring healthcare setting administration is burdensome',
      'Infusion reactions and anaphylaxis risk require pre-medication and monitoring',
      'Very high cost (~$300,000/year) limits access despite clinical benefit in refractory patients',
    ],
    source: 'Horizon/Amgen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Uloric',
    generic_name: 'febuxostat',
    company: 'Takeda',
    indication: 'Gout',
    indication_specifics: 'Chronic management of hyperuricemia in gout patients who have inadequate response to or intolerance of allopurinol',
    mechanism: 'Selective xanthine oxidase inhibitor (non-purine) that blocks the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid',
    mechanism_category: 'urate_lowering',
    molecular_target: 'Xanthine oxidase',
    phase: 'Approved',
    primary_endpoint: 'Serum uric acid <6 mg/dL',
    key_data: 'CONFIRMS: 67% achieved sUA <6 mg/dL with febuxostat 80mg vs 42% with allopurinol 300mg (p<0.001); CARES: non-inferior CV safety vs allopurinol but FDA black box warning for CV death signal',
    line_of_therapy: 'Second-line (after allopurinol failure/intolerance)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Superior urate-lowering efficacy vs standard-dose allopurinol in head-to-head trials',
      'Does not require renal dose adjustment, advantageous for gout patients with CKD',
      'Non-purine structure avoids hypersensitivity risk associated with allopurinol in HLA-B*5801+ patients',
    ],
    weaknesses: [
      'FDA black box warning for cardiovascular death based on CARES trial signal limits prescribing confidence',
      'Restricted to second-line use after allopurinol failure per FDA labeling',
      'Higher cost than generic allopurinol with prescribing constraints reducing utilization',
    ],
    source: 'Takeda 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zurampic',
    generic_name: 'lesinurad',
    company: 'AstraZeneca',
    indication: 'Gout',
    indication_specifics: 'Hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor when XOI alone is insufficient',
    mechanism: 'Selective uric acid reabsorption inhibitor (URAT1 and OAT4 inhibitor) that promotes renal uric acid excretion by blocking urate transporters in the proximal tubule',
    mechanism_category: 'urate_lowering',
    molecular_target: 'URAT1 / OAT4',
    phase: 'Approved',
    primary_endpoint: 'Serum uric acid <6 mg/dL (combination with XOI)',
    key_data: 'CLEAR 1 & 2: Lesinurad 200mg + allopurinol achieved sUA <6 mg/dL in 54% vs 28% with allopurinol alone (p<0.001); generally well-tolerated when used with XOI',
    line_of_therapy: 'Add-on to xanthine oxidase inhibitor',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Complementary mechanism to XOIs by targeting renal urate excretion rather than production',
      'Combination with allopurinol significantly increases target attainment rates',
      'Oral once-daily dosing simplifies addition to existing XOI regimen',
    ],
    weaknesses: [
      'Must be used in combination with XOI; monotherapy increases renal adverse event risk',
      'Renal safety concerns (serum creatinine elevations) require monitoring',
      'Limited commercial availability after AstraZeneca discontinued standalone product in some markets',
    ],
    source: 'AstraZeneca 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 15. Hyperuricemia
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Allopurinol',
    generic_name: 'allopurinol',
    company: 'Generic',
    indication: 'Hyperuricemia',
    indication_specifics: 'Chronic hyperuricemia with or without gout for long-term serum uric acid management',
    mechanism: 'Xanthine oxidase inhibitor (purine analog) that competitively blocks xanthine oxidase and its metabolite oxypurinol provides sustained enzyme inhibition, reducing uric acid production',
    mechanism_category: 'urate_lowering',
    molecular_target: 'Xanthine oxidase',
    phase: 'Approved',
    primary_endpoint: 'Serum uric acid <6 mg/dL',
    key_data: 'Decades of clinical experience; target attainment of 60-80% when dose-titrated to target; ALL-HEART: no cardiovascular benefit for allopurinol in ischemic heart disease patients',
    line_of_therapy: 'First-line',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Extremely low cost as a widely available generic, ensuring universal access',
      'Decades of safety experience with well-characterized adverse event profile',
      'Guideline-recommended first-line therapy with strong evidence base when dose-titrated',
    ],
    weaknesses: [
      'Hypersensitivity syndrome (AHS) can be fatal, especially in HLA-B*5801+ patients',
      'Requires dose titration and renal adjustment, often leading to under-dosing in practice',
      'ALL-HEART trial showed no cardiovascular benefit despite epidemiologic associations',
    ],
    source: 'ACR Guidelines 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Febuxostat',
    generic_name: 'febuxostat',
    company: 'Takeda',
    indication: 'Hyperuricemia',
    indication_specifics: 'Chronic hyperuricemia in patients intolerant or refractory to allopurinol',
    mechanism: 'Non-purine selective xanthine oxidase inhibitor providing potent urate-lowering without the hypersensitivity risk of purine-based XOIs',
    mechanism_category: 'urate_lowering',
    molecular_target: 'Xanthine oxidase',
    phase: 'Approved',
    primary_endpoint: 'Serum uric acid <6 mg/dL',
    key_data: 'FACT/APEX: 53-62% achieved sUA <6 mg/dL with 80mg vs 21% with allopurinol 300mg; effective across renal function spectrum; FAST trial showed non-inferior CV safety vs allopurinol in Europe',
    line_of_therapy: 'Second-line',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'More potent urate-lowering than standard-dose allopurinol across all studies',
      'No renal dose adjustment needed, advantageous for hyperuricemia patients with renal impairment',
      'European FAST trial provided more reassuring CV safety data than US CARES trial',
    ],
    weaknesses: [
      'FDA black box warning for CV death (US) despite European FAST data, limiting physician confidence',
      'Higher cost than generic allopurinol restricts use to second-line per guidelines and payer policies',
      'Liver function monitoring recommended due to hepatic adverse event reports',
    ],
    source: 'Takeda 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'AR882',
    generic_name: 'AR882',
    company: 'Arthrosi Therapeutics',
    indication: 'Hyperuricemia',
    indication_specifics: 'Hyperuricemia with or without gout as a novel selective URAT1 inhibitor for potent uricosuric monotherapy',
    mechanism: 'Highly selective URAT1 inhibitor that blocks the primary renal uric acid reabsorption transporter to promote uric acid excretion with minimal off-target transporter inhibition',
    mechanism_category: 'urate_lowering',
    molecular_target: 'URAT1',
    phase: 'Phase 3',
    primary_endpoint: 'Serum uric acid <5 mg/dL',
    key_data: 'Phase 2b: 73% achieved sUA <5 mg/dL with AR882 75mg at week 12 (p<0.001 vs placebo); potent urate-lowering as monotherapy; favorable renal safety with no creatinine signals; Phase 3 DISSOLVE ongoing',
    line_of_therapy: 'First-line or second-line (investigational)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'High selectivity for URAT1 may improve renal safety profile vs less selective uricosurics',
      'Potent monotherapy efficacy achieving aggressive sUA target <5 mg/dL in majority of patients',
      'Oral once-daily with no XOI co-requirement, unlike lesinurad',
    ],
    weaknesses: [
      'Phase 3 data still pending; must confirm Phase 2 efficacy and safety at scale',
      'Uricosuric mechanism requires adequate renal function, limiting use in advanced CKD',
      'Renal stone risk inherent to uricosuric mechanism needs long-term safety evaluation',
    ],
    source: 'Arthrosi Therapeutics 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 16. Type 1 Diabetes
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Tzield',
    generic_name: 'teplizumab',
    company: 'Provention Bio / Sanofi',
    indication: 'Type 1 Diabetes',
    indication_specifics: 'Delay of Stage 3 T1D onset in at-risk individuals (≥8 years) with Stage 2 T1D (≥2 autoantibodies and dysglycemia)',
    mechanism: 'Anti-CD3 monoclonal antibody that modulates T-cell-mediated autoimmune destruction of pancreatic beta cells by inducing partial T-cell exhaustion and expanding regulatory T cells',
    mechanism_category: 'anti_cd3',
    molecular_target: 'CD3 (T-cell receptor complex)',
    phase: 'Approved',
    primary_endpoint: 'Time to clinical T1D diagnosis (Stage 3)',
    key_data: 'TN-10 (At-Risk): Median delay of clinical T1D onset by ~2 years (50 months vs 25 months, HR 0.41, p=0.006); first disease-modifying therapy approved for T1D prevention',
    line_of_therapy: 'Pre-clinical T1D (disease interception)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First and only therapy to delay clinical T1D onset, establishing entirely new treatment paradigm',
      'Biomarker-driven patient selection (autoantibodies + dysglycemia) enables precision interception',
      'Single 14-day IV course provides durable benefit lasting years without chronic treatment',
    ],
    weaknesses: [
      'Requires identification of at-risk individuals via screening, which is not yet standard practice',
      'Cytokine release syndrome and lymphopenia during infusion require monitoring',
      'Delays but does not prevent T1D; long-term durability and need for retreatment unknown',
    ],
    source: 'Provention Bio / Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lantus/Toujeo',
    generic_name: 'insulin glargine',
    company: 'Sanofi',
    indication: 'Type 1 Diabetes',
    indication_specifics: 'T1D basal insulin replacement as part of basal-bolus regimen for glycemic control',
    mechanism: 'Long-acting basal insulin analog that forms microprecipitates after subcutaneous injection, providing slow, peakless insulin release over ~24 hours to mimic physiologic basal insulin secretion',
    mechanism_category: 'insulin_analog',
    molecular_target: 'Insulin receptor',
    phase: 'Approved',
    primary_endpoint: 'HbA1c reduction',
    key_data: 'Lantus: >20 years clinical experience; Toujeo (U300): EDITION trials showed similar HbA1c reduction with 14% less nocturnal hypoglycemia vs Lantus; flat PK/PD profile over 36 hours',
    line_of_therapy: 'First-line basal insulin',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Established gold standard for basal insulin in T1D with decades of clinical experience',
      'Toujeo U300 offers flatter profile and less nocturnal hypoglycemia vs original glargine',
      'Widely available including biosimilar options (Semglee, Rezvoglar) reducing cost barriers',
    ],
    weaknesses: [
      'Exogenous insulin cannot replicate physiologic glucose-responsive insulin secretion',
      'Hypoglycemia remains a persistent safety concern despite improved PK profiles',
      'Daily injection burden contributes to patient fatigue and adherence challenges over lifetime',
    ],
    source: 'Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'VX-880',
    generic_name: 'VX-880',
    company: 'Vertex Pharmaceuticals',
    indication: 'Type 1 Diabetes',
    indication_specifics: 'T1D with impaired hypoglycemic awareness and severe hypoglycemic episodes for functional cure via stem cell-derived islet cell replacement',
    mechanism: 'Allogeneic stem cell-derived fully differentiated pancreatic islet cell therapy infused into the hepatic portal vein to restore endogenous insulin production and glucose-responsive regulation',
    mechanism_category: 'islet_cell_therapy',
    molecular_target: 'Pancreatic beta cell replacement',
    phase: 'Phase 1/2',
    primary_endpoint: 'Insulin independence (elimination of exogenous insulin) and HbA1c <7% without severe hypoglycemia',
    key_data: 'Phase 1/2: Multiple patients achieved insulin independence at full dose; first patient maintained insulin-free for >1 year with HbA1c <7%; robust C-peptide production restored; requires immunosuppression',
    line_of_therapy: 'Curative intent (investigational)',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Potential functional cure for T1D with complete insulin independence demonstrated in early patients',
      'Scalable stem cell manufacturing could overcome donor islet supply limitations',
      'Glucose-responsive insulin secretion restores physiologic regulation unlike exogenous insulin',
    ],
    weaknesses: [
      'Chronic immunosuppression required creates infection, malignancy, and renal toxicity risks',
      'Very early clinical stage with limited patient numbers; durability beyond 1-2 years unproven',
      'Complex manufacturing and portal vein infusion procedure limit scalability and access',
    ],
    source: 'Vertex Pharmaceuticals 2024',
    last_updated: '2025-01-15',
  },

  // ─────────────────────────────────────────────────────────────────────────────
  // 17. Hyperlipidemia
  // ─────────────────────────────────────────────────────────────────────────────
  {
    asset_name: 'Repatha',
    generic_name: 'evolocumab',
    company: 'Amgen',
    indication: 'Hyperlipidemia',
    indication_specifics: 'Primary hyperlipidemia and established ASCVD as adjunct to statins for additional LDL-C reduction and cardiovascular risk reduction',
    mechanism: 'Fully human anti-PCSK9 monoclonal antibody that binds circulating PCSK9, preventing LDL receptor degradation and enhancing hepatic LDL-C clearance from plasma',
    mechanism_category: 'pcsk9_inhibitor',
    molecular_target: 'PCSK9',
    phase: 'Approved',
    primary_endpoint: 'LDL-C % change from baseline',
    key_data: 'FOURIER: 59% LDL-C reduction; 15% RRR in MACE (p<0.001); 20% reduction in MI, 21% reduction in stroke; 8-year open-label extension confirms durable safety with very low LDL-C',
    line_of_therapy: 'Add-on to maximally tolerated statin',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'FOURIER provides robust cardiovascular outcomes data with 15% MACE reduction',
      'Consistent ~60% LDL-C reduction enables ultra-low LDL-C targets in highest-risk patients',
      'Long-term safety data over 8+ years confirms no signals with very low LDL-C levels',
    ],
    weaknesses: [
      'High biologic cost creates significant payer barriers despite price reductions',
      'Injection route and cold storage less convenient than oral therapies like bempedoic acid',
      'Generic statin + ezetimibe provides adequate LDL-C reduction for many patients at far lower cost',
    ],
    source: 'Amgen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nexletol',
    generic_name: 'bempedoic acid',
    company: 'Esperion Therapeutics',
    indication: 'Hyperlipidemia',
    indication_specifics: 'Primary hyperlipidemia and ASCVD as adjunct to diet and statin therapy for additional LDL-C reduction, including statin-intolerant patients',
    mechanism: 'ATP citrate lyase (ACL) inhibitor that blocks cholesterol synthesis upstream of HMG-CoA reductase, acting as a prodrug activated only in the liver to avoid muscle-related side effects',
    mechanism_category: 'acl_inhibitor',
    molecular_target: 'ATP citrate lyase',
    phase: 'Approved',
    primary_endpoint: 'LDL-C % change from baseline',
    key_data: 'CLEAR Outcomes: 13% RRR in MACE in statin-intolerant patients (p=0.004); ~18% LDL-C reduction as monotherapy, ~38% combined with ezetimibe; first non-statin oral to show MACE reduction',
    line_of_therapy: 'Add-on to statin or monotherapy for statin-intolerant patients',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Oral once-daily pill with no injection required, providing convenience advantage over PCSK9 inhibitors',
      'CLEAR Outcomes is first trial to demonstrate MACE reduction with a non-statin oral lipid-lowering drug',
      'Liver-specific prodrug activation avoids muscle side effects, ideal for statin-intolerant patients',
    ],
    weaknesses: [
      'Modest LDL-C reduction (~18%) significantly lower than PCSK9 inhibitors (~60%)',
      'Elevated uric acid and gout/tendon rupture risk are unique safety signals',
      'Limited use in patients already on high-intensity statins where additional LDL-C reduction is modest',
    ],
    source: 'Esperion 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Leqvio',
    generic_name: 'inclisiran',
    company: 'Novartis',
    indication: 'Hyperlipidemia',
    indication_specifics: 'Primary hyperlipidemia and ASCVD for LDL-C reduction with twice-yearly in-office dosing',
    mechanism: 'siRNA targeting hepatic PCSK9 mRNA for sustained silencing of PCSK9 protein production, providing durable LDL-C reduction with infrequent dosing',
    mechanism_category: 'pcsk9_sirna',
    molecular_target: 'PCSK9 mRNA',
    phase: 'Approved',
    primary_endpoint: 'LDL-C % change from baseline',
    key_data: 'ORION-10/11: ~50% LDL-C reduction maintained with twice-yearly dosing; ORION-4 cardiovascular outcomes trial ongoing with results expected 2026; consistent efficacy across populations',
    line_of_therapy: 'Add-on to maximally tolerated statin',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Twice-yearly physician-administered dosing eliminates adherence as a variable in LDL-C management',
      'Novel siRNA mechanism provides durable PCSK9 silencing between doses',
      'In-office administration creates reliable touchpoint for cardiovascular risk management',
    ],
    weaknesses: [
      'ORION-4 cardiovascular outcomes data not yet available; MACE reduction unconfirmed',
      'In-office injection every 6 months requires healthcare visits, adding system burden',
      'Slightly lower peak LDL-C reduction (~50%) vs monoclonal antibody PCSK9 inhibitors (~60%)',
    ],
    source: 'Novartis 2024',
    last_updated: '2025-01-15',
  },
];
